Latest MD Biosciences Stories
MD Biosciences enters into an agreement with Janssen Research & Development, LLC to screen an extensive library of compounds with its proprietary Senerga® Phenotypic Screening Platform.
A large animal model of post-operative pain (POP) that provides greater translational relevance for the evaluation of local treatments of POP compared with existing rodent models of incisional
MD Biosciences focuses on rapid and cost effective models of psoriasis involving the IL-23/Th17 axis in order to provide companies alternatives to complex and cost prohibitive xenotransplantation
Expansion provides increased capacity, ability to add new models as well as continue the development of new methods and biomarkers that bring clinical insight to the nonclinical drug development
The porcine sciatica model can evaluate efficacy and PK/PD from the same subject and may provide more clinically relevant data at preclinical stages minimizing expensive failures. St
MD Biosciences, a global biotechnology company focused in inflammations & neurology research will showcase its pre-clinical capabilities at the 2008 Neuroscience Conference in Washington, DC, November 15 - 19th, 2008, booth 1825.
MD Biosciences, a global biotechnology company focused in inflammations & neurology research will showcase its inflammations related pre-clinical services and research products at the 15th International Inflammation Research Association (IRA) Conference, September 21-24, Chantilly, VA.